STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Overview of Twist Bioscience Corp

Twist Bioscience Corp is a pioneering synthetic biology company that has redefined the process of DNA synthesis using a proprietary semiconductor-based manufacturing platform. The company leverages innovative technology to produce high-quality synthetic DNA rapidly and cost-effectively. This breakthrough approach, characterized by synthesizing DNA on silicon rather than traditional plastic wells, positions Twist Bioscience as a disruptive force in the biotechnological landscape, driving advances in applications from biomedical research to industrial biotechnology.

Proprietary Technology and Manufacturing Process

At the heart of Twist Bioscience's operations is a state-of-the-art synthetic DNA manufacturing process. By employing a 10,000-well silicon platform, the company sidesteps the limitations inherent in conventional methods. The integration of semiconductor technology not only minimizes production inefficiencies but also ensures high throughput, which is crucial for applications requiring rapid gene synthesis and customization. This technical ingenuity underpins the company's ability to deliver:

  • High-quality oligonucleotides
  • Custom genes and genetic pathways
  • Complex chassis and complete genomes

Business Model and Revenue Generation

Twist Bioscience's business model is built on the dual pillars of technology licensing and direct sales. The company generates revenue by offering its synthetic DNA products to a wide range of customers including academic research institutions, biotechnology firms, and industrial manufacturers. Its cost-effective, rapid production capabilities allow clients to accelerate their research and development efforts, thereby reducing time-to-market for various applications. This operational efficiency is not only beneficial to its clients but also reinforces the company’s reputation for reliability and scalability in the synthetic biology market.

Market Position and Competitive Landscape

Operating in a highly specialized niche, Twist Bioscience has carved a unique position in the competitive synthetic biology ecosystem. The company differentiates itself through its disruptive manufacturing process and its capacity to produce synthetic biology tools at scale. In a market where reliability, speed, and cost-efficiency are paramount, Twist Bioscience’s strategic focus on overcoming production inefficiencies positions it as a significant player. Its technology challenges traditional paradigms and compels competitors to reconsider conventional manufacturing methods, thereby affirming its role as an innovator rather than a mere participant in the industry.

Applications and Industry Impact

The technology developed by Twist Bioscience has far-reaching implications across numerous sectors. In the field of biomedical research and personalized medicine, its rapid DNA synthesis paves the way for new diagnostics, targeted therapies, and advanced research into genetic disorders. Beyond healthcare, the company’s synthetic biology tools enable innovations in sustainable chemical production and improved agricultural practices, broadening the scope of applications into:

  • Biopharmaceutical research: Accelerating drug discovery and genetic screening.
  • Industrial biotechnology: Optimizing production processes for chemicals and materials.
  • Environmental monitoring: Developing in vivo diagnostics and biodetection solutions.

This multi-sector applicability underscores the versatility and transformative potential of Twist Bioscience's platform. By industrializing the engineering of biology, the company not only enhances research capabilities but also contributes significantly to sectors that rely on synthetic DNA for innovation and efficiency.

Operational Excellence and Research Ecosystem

Central to the success of Twist Bioscience is its commitment to operational excellence and continuous innovation. The company collaborates with a diverse ecosystem of researchers, academic institutions, and industrial partners, fostering an environment where technological breakthroughs are routinely translated into practical solutions. This collaborative approach ensures that every advancement in its manufacturing process is both rigorously validated and immediately deployable across a spectrum of research and industrial applications.

Scientific and Technical Expertise

Twist Bioscience is driven by a deep reservoir of scientific and technical expertise. The company’s team, comprised of leading experts in synthetic biology, semiconductor physics, and bioengineering, is instrumental in refining its technology and pushing the boundaries of what is possible in DNA synthesis. This expertise not only strengthens the company’s competitive position but also instills confidence in its ability to deliver reliable, high-quality synthetic biology products that meet the evolving needs of modern research and industry.

Integration into the Broader Biotechnology Landscape

The innovations from Twist Bioscience resonate well within the broader biotechnology and life sciences arenas. Its approach to DNA synthesis using semiconductor-based technology is widely recognized for its potential to revolutionize how genetic materials are produced and utilized. This integration of advanced material science with biotechnology exemplifies the cross-disciplinary innovation that is becoming increasingly important. Researchers and industrial partners alike appreciate the capacity for simultaneous high throughput and high precision, enabling a smoother transition from conceptual breakthroughs to tangible products.

Commitment to Quality and Reliability

Quality control and reliability are fundamental to Twist Bioscience’s operations. The company’s advanced manufacturing process ensures consistency and precision in synthetic DNA production. By employing robust quality assurance protocols throughout its production cycle, Twist Bioscience provides products that research institutions and industry players can depend upon for critical applications. This unwavering focus on quality not only supports current operational needs but also cements the company’s reputation as a trustworthy provider of synthetic biology tools.

Position within the Competitive Landscape

While the synthetic biology sector is competitive, Twist Bioscience’s distinctive approach allows it to maintain a unique market niche. Its semiconductor-based platform, coupled with the extensive scale and precision of production, sets it apart from more traditionally operated competitors. The company’s strategy of addressing the inherent inefficiencies of standard DNA synthesis methods resonates with clients looking for innovative solutions. This unique value proposition has enabled Twist Bioscience to develop a strong foothold in its primary markets, particularly in regions known for high research and development activity.

Conclusion

In summary, Twist Bioscience Corp represents a significant advancement in synthetic biology. Through its disruptive semiconductor-based synthetic DNA platform, the company not only accelerates research and industrial processes but also redefines the standards of cost efficiency and production quality. Its integrated approach, encompassing innovative technology, rigorous quality control, a collaborative research ecosystem, and a clear focus on operational excellence, makes it a compelling case study in modern biotechnology innovations. The breadth of its applications and its ability to deliver high-quality synthetic DNA at scale underscore its impact on the biotechnology industry and its sustained position in the competitive landscape.

Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced participation in two upcoming virtual investor conferences. CEO Emily Leproust and CFO Jim Thorburn will present at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 AM ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:50 PM ET. Both presentations will be webcast live and available for replay for 30 days. Twist Bioscience is known for its innovative synthetic DNA technology, providing products across various sectors including healthcare and agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
conferences
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announces its support for the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research. This initiative aims to advance ethical standards in engineering biology, which has significantly impacted fields like medicine and agriculture. The U.S. engineering biology sector contributed 5.1% to GDP in 2016. Twist emphasizes its commitment to biosecurity and ethical practices while encouraging collaboration among the scientific community to ensure responsible innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) reported strong financial results for Q2 FY2021, ending March 31, 2021. Total orders reached $41.7 million, up from $24.6 million year-over-year. Revenue grew to $31.2 million, compared to $19.3 million in the prior year. However, net loss for the quarter increased to $37.9 million, or $0.78 per share. The cash position stood robust at $555.7 million. The company is optimistic about growth in the second half of the fiscal year, particularly in its NGS and synthetic biology segments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.93%
Tags
Rhea-AI Summary

Twist Bioscience (Nasdaq: TWST) has announced a collaboration with Vivlion GmbH to develop CRISPR gRNA libraries for various applications in genome engineering and drug development. This partnership leverages Twist's high-quality synthetic DNA production capabilities and Vivlion's innovative 3Cs technology for creating uniform CRISPR libraries. The collaboration aims to enhance genomic research efficiency, enabling faster gene function analysis. The joint effort is expected to significantly impact R&D in functional genomics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has announced plans to release its financial results for the fiscal 2021 second quarter on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The financial results will be accessible on the company's website under Investor Relations. Twist Bioscience is focused on pioneering DNA synthesis technology, catering to diverse industries including healthcare and agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences earnings
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has expanded its lease for the 'Factory of the Future' near Portland, Oregon, adding approximately 100,000 square feet to its existing 110,000-square-foot facility. This expansion supports the company's planned growth in synthetic DNA, including potential verticals like DNA data storage. CEO Emily M. Leproust emphasized the need for strategic space planning for future market opportunities. The financial commitment for the expansion begins in 2022, aiming to bolster Twist’s capabilities in synthetic biology and genomics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.8%
Tags
none
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has announced a partnership with Pure Biologics to enhance the discovery of immuno-oncology antibody-based drugs. Through this collaboration, Twist Biopharma will provide Pure Biologics with access to synthetic antibody phage display libraries, optimized with advanced techniques including AI and big data analytics. The partnership aims to identify and optimize novel antibody candidates for therapeutic applications, with Pure Biologics committing to annual technology access fees and future milestone payments for successful outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (TWST) announced it will acquire rights to a GPCR library and proprietary Twist Antibody Optimization software developed with Distributed Bio. This acquisition, initiated in 2016, enhances Twist's capabilities in antibody discovery using its silicon DNA synthesis platform. The GPCR library contributes to a 'Library of Libraries' with over 10 billion antibodies, facilitating optimized therapeutics. The financial terms remain undisclosed, and the move supports Twist's growth in synthetic biology and genomics, aiming to advance drug discovery and development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
Rhea-AI Summary

AcornMed Biotechnology has announced a partnership with Twist Bioscience to integrate Twist's next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed's cancer precision medicine tests. This collaboration aims to enhance genetic analysis for better treatment strategies. Dr. Feng Lou, CTO of AcornMed, emphasized the importance of Twist's quality DNA synthesis in improving diagnostic accuracy. The partnership is expected to positively influence patient treatment and healthcare costs in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) has partnered with Stanford University's Innovative Medicines Accelerator to provide access to its antibody discovery services and its innovative 'Library of Libraries.' This collaboration will enable Stanford researchers to utilize Twist’s advanced synthetic antibody libraries for various therapeutic targets. Twist will receive technology access fees and share in revenue from outlicensed antibodies. The first project aims to discover novel antibodies targeting a neuroscience application. The partnership showcases Twist's commitment to advancing biologics discovery through collaboration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $39.82 as of April 14, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.3B.

What is Twist Bioscience's core business?

Twist Bioscience focuses on synthetic biology by utilizing a proprietary semiconductor-based platform to synthesize high-quality DNA. Its core business involves manufacturing synthetic DNA for research, industrial biotechnology, and biomedical applications.

How does Twist Bioscience's technology differ from traditional methods?

The company synthesizes DNA on silicon rather than on conventional plastic plates, enabling cost-effective, rapid, and high-throughput production while overcoming common inefficiencies in traditional synthesis methods.

Which industries benefit from Twist Bioscience's products?

Industries ranging from biomedical research and personalized medicine to industrial biotechnology and sustainable chemical production benefit from their high-quality synthetic DNA products.

What are the primary products provided by Twist Bioscience?

Twist Bioscience produces a range of synthetic biology tools including oligonucleotides, genes, genetic pathways, chassis, and complete genomes, all synthesized using their advanced silicon-based platform.

How does the company's business model support its operations?

The company generates revenue through direct sales and technology licensing, offering high-quality synthetic DNA products that enhance research capabilities and industrial production efficiency.

What competitive advantages does Twist Bioscience hold in the synthetic biology market?

Their proprietary technology, which leverages semiconductor manufacturing techniques, allows them to produce DNA faster and more cost-effectively than traditional methods, positioning them uniquely in the competitive landscape.

Who are the primary customers of Twist Bioscience?

Twist Bioscience serves a diverse customer base including academic research institutions, biotechnology companies, and industrial manufacturers requiring reliable synthetic DNA production for various applications.

How does Twist Bioscience ensure the quality of its synthetic DNA products?

By integrating rigorous quality control protocols within its manufacturing process, the company ensures consistent and precise production, making its products dependable for critical research and industrial applications.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.32B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO